Omnicell (NASDAQ:OMCL) Issues FY 2025 Earnings Guidance

Omnicell (NASDAQ:OMCL) updated its FY 2025 earnings guidance on Friday. The company provided EPS guidance of 1.650-1.850 for the period, compared to the consensus EPS estimate of 1.780. The company issued revenue guidance of $1.1 billion-$1.2 billion, compared to the consensus revenue estimate of $1.1 billion. Omnicell also updated its Q1 2025 guidance to 0.150-0.250 EPS.

Omnicell Price Performance

Shares of NASDAQ OMCL opened at $34.74 on Friday. The stock has a market cap of $1.62 billion, a P/E ratio of 128.66, a P/E/G ratio of 7.53 and a beta of 0.85. The firm’s 50-day simple moving average is $39.16 and its 200 day simple moving average is $42.64. Omnicell has a fifty-two week low of $25.12 and a fifty-two week high of $55.75. The company has a quick ratio of 1.22, a current ratio of 1.37 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. Equities analysts expect that Omnicell will post 1.09 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have commented on OMCL. Bank of America dropped their price target on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a research report on Monday, January 6th. Wells Fargo & Company reduced their target price on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. StockNews.com downgraded Omnicell from a “buy” rating to a “hold” rating in a research report on Monday. Benchmark reaffirmed a “buy” rating and set a $62.00 target price on shares of Omnicell in a research report on Tuesday, February 4th. Finally, JPMorgan Chase & Co. reduced their target price on Omnicell from $44.00 to $36.00 and set a “neutral” rating for the company in a report on Thursday, March 20th. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $51.00.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.